KRAS and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC), TP53TG1 works via the miR-96/KRAS axis through directly binding to tumor suppressor miR-96 and preventing miR-96 from binding to its target oncogene KRAS, thus elevating KRAS expression [20].